In the following video, Motley Fool health-care analyst David Williamson takes investors through what to expect from Bristol-Myers Squibb's (BMY 0.06%) upcoming earnings report and the important things to watch from this company moving forward.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Foolish Preview: Bristol-Myers Squibb
By Dave Williamson
–
Jan 23, 2013 at 7:33PM
NYSE: BMY
Bristol Myers Squibb
Market Cap
$95B
Today's Change
(0.06%) $0.03
Current Price
$46.87
Price as of June 20, 2025, 3:58 p.m. ET
What to expect from Bristol-Myers Squibb's earnings report.
David Williamson owns shares of Pfizer. The Motley Fool recommends Gilead Sciences. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Bristol Myers Squibb
BMY
$46.87
(0.06%)
$0.03
Pfizer
PFE
$23.98
(0.40%)
$0.10
Gilead Sciences
GILD
$108.69
(0.64%)
$0.69
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
What Most-Favored-Nation Status Could Mean for Pharmaceutical Stocks
This High-Yield Pharma Stock Looks Like an Incredible Bargain
Is Bristol Myers Squibb's High-Yielding Dividend Safe?
Beat the S&P 500 With This Cash-Gushing Dividend Stock
3 Deeply Discounted Dividend Stocks to Buy Today
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.